AbbVie Inc (ABBV)

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend PR Newswire NORTH CHICAGO, Ill., June 18, 2026 NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The...

Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower PR Newswire RENO, Nev., June 16...

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck...

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting...

Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics

Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer...

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 PR Newswire NORTH CHICAGO, Ill., June 8, 2026 Data being presented...

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill., June 2, 2026 NORTH...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults PR Newswire NORTH CHICAGO...

Form SD - Specialized disclosure report

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in...

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an...

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection PR Newswire...

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline PR Newswire NORTH...